{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:21:15Z","timestamp":1791570075510,"version":"4.3.4"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The global impact of zoonotic viral outbreaks underscores the pressing need for innovative antiviral strategies, particularly against respiratory zoonotic RNA viruses. These viruses possess a high potential to trigger future epidemics and pandemics due to their high mutation rate, broad host range and efficient spread through airborne transmission. Recent pandemics caused by coronaviruses and influenza A viruses underscore the importance of developing targeted antiviral strategies. Single-domain antibodies (sdAbs), originating from camelids, also known as nanobodies or VHHs (Variable Heavy domain of Heavy chain antibodies), have emerged as promising tools to combat current and impending zoonotic viral threats. Their unique structure, coupled with attributes like robustness, compact size, and cost-effectiveness, positions them as strong alternatives to traditional monoclonal antibodies. This review describes the pivotal role of sdAbs in combating respiratory zoonotic viruses, with a primary focus on enhancing sdAb antiviral potency through optimization techniques and diverse administration strategies. We discuss both the promises and challenges within this dynamically growing field.<\/jats:p>","DOI":"10.3389\/fmolb.2024.1389548","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:16:56Z","timestamp":1715231816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Next generation single-domain antibodies against respiratory zoonotic RNA viruses"],"prefix":"10.3389","volume":"11","author":[{"given":"Iris C.","family":"Swart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis A. M.","family":"De Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend-Jan","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105778","DOI":"10.1016\/j.antiviral.2023.105778","article-title":"Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters","volume":"221","author":"Aksu","year":"2024","journal-title":"Antivir. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/v13040537","article-title":"Key factors that enable the pandemic potential of RNA viruses and inter-species transmission: a systematic review","volume":"13","author":"Alvarez-Munoz","year":"2021","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies","volume":"414","author":"Arbabi Ghahroudi","year":"1997","journal-title":"FEBS Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s13205-021-02647-5","article-title":"Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)","volume":"11","author":"Bessalah","year":"2021","journal-title":"3 Biotech."},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijbiomac.2022.12.284","article-title":"Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: current update","volume":"229","author":"Bhattacharya","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13701","DOI":"10.1073\/pnas.1007465107","article-title":"Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge","volume":"107","author":"Bommakanti","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B9","first-page":"37","article-title":"ALX-0171: safety and therapeutic potential of an inhaled anti-RSV Nanobody","volume":"1","author":"Bruyn","year":"2015","journal-title":"RDD Eur. 2015"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1126\/science.286.5446.1921","article-title":"Predicting the evolution of human influenza A","volume":"286","author":"Bush","year":"1999","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.1128\/JVI.03178-13","article-title":"Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge","volume":"88","author":"Cardoso","year":"2014","journal-title":"J. Virology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"690742","DOI":"10.3389\/fimmu.2021.690742","article-title":"Prospects of neutralizing nanobodies against SARS-CoV-2","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2200932","DOI":"10.1002\/smtd.202200932","article-title":"An engineered IgG\u2013VHH bispecific antibody against SARS\u2010CoV\u20102 and its variants","volume":"6","author":"Chi","year":"","journal-title":"Small Methods"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-022-00912-4","article-title":"An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants","volume":"7","author":"Chi","year":"","journal-title":"Sig Transduct. Target Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ijc.10212","article-title":"Efficient tumor targeting by single-domain antibody fragments of camels","volume":"98","author":"Cortez-Retamozo","year":"2002","journal-title":"Int. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tim.2020.12.006","article-title":"Slaying SARS-CoV-2 One (Single-domain) antibody at a time","volume":"29","author":"Czajka","year":"2021","journal-title":"Trends Microbiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.10.531533","article-title":"Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike","author":"De Cae","year":"2023","journal-title":"Microbiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections","volume":"8","author":"De Vlieger","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tim.2019.08.010","article-title":"Influenza A virus hemagglutinin\u2013neuraminidase\u2013receptor balance: preserving virus motility","volume":"28","author":"de Vries","year":"2020","journal-title":"Trends Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"17806","DOI":"10.1038\/s41598-020-74761-y","article-title":"Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2","volume":"10","author":"Dong","year":"2020","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3389\/fimmu.2016.00619","article-title":"Expression cloning and production of human heavy-chain-only antibodies from murine transgenic plasma cells","volume":"7","author":"Drabek","year":"2016","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-0716-2075-5_6","article-title":"A transgenic heavy chain IgG mouse platform as a source of high affinity fully human single-domain antibodies for therapeutic applications","volume-title":"Single-domain antibodies: methods and protocols","author":"Drabek","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1021\/acs.analchem.7b05217","article-title":"Fenobody: a ferritin-displayed nanobody with high apparent affinity and half-life extension","volume":"90","author":"Fan","year":"2018","journal-title":"Anal. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1021\/acsptsci.3c00042","article-title":"Emerging landscape of nanobodies and their neutralizing applications against SARS-CoV-2 virus","volume":"6","author":"Feng","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/mco2.60","article-title":"A potent neutralizing nanobody against SARS\u2010CoV\u20102 with inhaled delivery potential","volume":"2","author":"Gai","year":"2021","journal-title":"MedComm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41467-021-27610-z","article-title":"A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo","volume":"13","author":"Hanke","year":"2022","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1038\/s41598-023-40919-7","article-title":"Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants","volume":"13","author":"Hollingsworth","year":"2023","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e103294","DOI":"10.1371\/journal.pone.0103294","article-title":"The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can Be increased by antibody valency","volume":"9","author":"Hufton","year":"2014","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1038\/s41598-023-31761-y","article-title":"The effect of SARS-CoV-2 variant on respiratory features and mortality","volume":"13","author":"Hughes","year":"2023","journal-title":"Sci. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1038\/s41467-021-25480-z","article-title":"A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19","volume":"12","author":"Huo","year":"2021","journal-title":"Nat. Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"853008","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a humanized anti-tnf\u03b1 NANOBODY\u00ae compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-tnf\u03b1 IgG","volume":"13","author":"Ishiwatari-Ogata","year":"2022","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15130","DOI":"10.1073\/pnas.0601108103","article-title":"Generation of heavy-chain-only antibodies in mice","volume":"103","author":"Janssens","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B42","doi-asserted-by":"publisher","first-page":"128191","DOI":"10.1016\/j.ijbiomac.2023.128191","article-title":"Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein","volume":"256","author":"Jiang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1086297","DOI":"10.3389\/fimmu.2023.1086297","article-title":"Analysis of the conserved protective epitopes of hemagglutinin on influenza A viruses","volume":"14","author":"Jiao","year":"2023","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"Nanobodies: a review of generation, Diagnostics and therapeutics","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"MAbs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"eabe6230","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","article-title":"The structural basis of nanobody unfolding reversibility and thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multi-domain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.bea.2022.100054","article-title":"Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses","volume":"4","author":"Lim","year":"2022","journal-title":"Biomed. Eng. Adv."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/ijms23031482","article-title":"Easily established and multifunctional synthetic nanobody libraries as research tools","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.xcrm.2023.100918","article-title":"Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice","volume":"4","author":"Liu","year":"","journal-title":"Cell. Rep. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"eadg9459","DOI":"10.1126\/sciimmunol.adg9459","article-title":"An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections","volume":"8","author":"Liu","year":"","journal-title":"Sci. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00253-017-8644-3","article-title":"Expression of single-domain antibody in different systems","volume":"102","author":"Liu","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/mabs.19909","article-title":"The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin","volume":"4","author":"Marks","year":"2012","journal-title":"MAbs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e73027","DOI":"10.7554\/eLife.73027","article-title":"Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape","volume":"10","author":"Mast","year":"2021","journal-title":"Elife"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/biom10121661","article-title":"Picomolar SARS-CoV-2 neutralization using multi-arm PEG nanobody constructs","volume":"10","author":"Moliner-Morro","year":"2020","journal-title":"Biomolecules"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1080\/22221751.2020.1827984","article-title":"Zoonotic and reverse zoonotic events of SARS-CoV-2 and their impact on global health","volume":"9","author":"Munir","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A guide to: generation and design of nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"FEBS J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"eabh0319","DOI":"10.1126\/sciadv.abh0319","article-title":"Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses","volume":"7","author":"Nambulli","year":"2021","journal-title":"Sci. Adv."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1039969","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2022","journal-title":"Front. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0161-5890(94)90001-9","article-title":"Anatomy of the antibody molecule","volume":"31","author":"Padlan","year":"1994","journal-title":"Mol. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1099\/0022-1317-33-1-159","article-title":"Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action","volume":"33","author":"Palese","year":"1976","journal-title":"J. General Virology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody\u00ae targeting the DR5 receptor","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1074\/jbc.R500020200","article-title":"The M2 proton channels of influenza A and B viruses","volume":"281","author":"Pinto","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e2101918118","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF02273711","article-title":"Delaying approval of a critical drug: safety, efficacy, economics, compassion","volume":"15","author":"Rosenberg","year":"1994","journal-title":"J. Med. Humanit"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"","journal-title":"FEBS J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42003-022-03866-z","article-title":"Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models","volume":"5","author":"Rossotti","year":"","journal-title":"Commun. Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.coph.2008.07.006","article-title":"Single-domain antibodies as building blocks for novel therapeutics","volume":"8","author":"Saerens","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(13)70286-X","article-title":"Pathogenesis of influenza-induced acute respiratory distress syndrome","volume":"14","author":"Short","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochimica Biophysica Acta (BBA) - General Subj."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature08182","article-title":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic","volume":"459","author":"Smith","year":"2009","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/v11010059","article-title":"From SARS to MERS, thrusting coronaviruses into the spotlight","volume":"11","author":"Song","year":"2019","journal-title":"Viruses"},{"key":"B78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2012.12.014","article-title":"Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2)","volume":"97","author":"Tillib","year":"2013","journal-title":"Antivir. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1038\/s41598-022-07952-4","article-title":"First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants","volume":"12","author":"Titong","year":"2022","journal-title":"Sci. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3390\/molecules27072198","article-title":"Structural insights into the design of synthetic nanobody libraries","volume":"27","author":"Vald\u00e9s-Tresanco","year":"2022","journal-title":"Molecules"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a novel CD16-specific single-domain antibody into multispecific natural killer cell engagers with potent ADCC","volume":"18","author":"van Faassen","year":"2021","journal-title":"Mol. Pharm."},{"key":"B82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies\u00ae as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.4049\/jimmunol.124.6.2708","article-title":"OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties","volume":"124","author":"Van Wauwe","year":"1980","journal-title":"J. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3390\/v14112485","article-title":"Cross-Reactive fc-fused single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza a virus infection","volume":"14","author":"Voronina","year":"2022","journal-title":"Viruses"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/s0161-5890(97)00146-6","article-title":"Comparison of llama VH sequences from conventional and heavy chain antibodies","volume":"34","author":"Vu","year":"1997","journal-title":"Mol. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.1073\/pnas.1708727114","article-title":"Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion","volume":"114","author":"Walls","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e54199","DOI":"10.15252\/embr.202154199","article-title":"Biparatopic sybodies neutralize SARS\u2010CoV\u20102 variants of concern and mitigate drug resistance","volume":"23","author":"Walter","year":"2022","journal-title":"EMBO Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e28309","DOI":"10.1371\/journal.pone.0028309","article-title":"Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein","volume":"6","author":"Wei","year":"2011","journal-title":"PLoS One"},{"key":"B90","doi-asserted-by":"publisher","first-page":"109869","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","article-title":"Single-domain antibodies as therapeutics against human viral diseases","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e1011804","DOI":"10.1371\/journal.ppat.1011804","article-title":"Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization","volume":"19","author":"Yang","year":"2023","journal-title":"PLOS Pathog."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11033-021-06819-7","article-title":"The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization","volume":"49","author":"Zebardast","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12951-022-01619-y","article-title":"A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode","volume":"20","author":"Zhao","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.3390\/ijms24044068","article-title":"Potent therapeutic strategies for COVID-19 with single-domain antibody immunoliposomes neutralizing SARS-CoV-2 and lip\/cGAMP enhancing protective immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2100099","DOI":"10.1002\/adtp.202100099","article-title":"Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants","volume":"4","author":"Zupancic","year":"2021","journal-title":"Adv. Ther."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2024.1389548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:17:01Z","timestamp":1715231821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2024.1389548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":99,"alternative-id":["10.3389\/fmolb.2024.1389548"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2024.1389548","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"article-number":"1389548"}}